J Med Microbiol NEW Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gençer, S.
Right arrow Articles by Batirel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gençer, S.
Right arrow Articles by Batirel, A.
Agricola
Right arrow Articles by Gençer, S.
Right arrow Articles by Batirel, A.
J Med Microbiol 57 (2008), 1028-1031; DOI: 10.1099/jmm.0.47299-0
© 2008 Society for General Microbiology
ISSN 1473-5644

Case Report

Angio-oedema as an unusual tolerable side effect of voriconazole therapy

Serap Gençer, Serdar Özer, Güler Demirhan, Öznur Ak and Ayse Batirel

Dr.Lütfi Kirdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Correspondence
Serap Gençer
segencer{at}tnn.net

Received 20 March 2007
Accepted 7 April 2008

Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.

Abbreviations: AmB, amphotericin B; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IA, invasive aspergillosis; VRC, voriconazole.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Pinto and R. C. Chan
Lack of Allergic Cross-Reactivity between Fluconazole and Voriconazole
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1715 - 1716.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2008 Society for General Microbiology.